Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 21 Melanoma 20 Carcinoma, Non-Small-Cell Lung 12 Neoplasm Metastasis 9 Pancreatic Neoplasms 8 Colorectal Neoplasms 8 Rectal Neoplasms 4 Triple Negative Breast Neoplasms 3 Multiple Myeloma 3 Lung Neoplasms 3 Colonic Neoplasms 3 Thyroid Neoplasms 2 Meningioma 2 Leukemia, Myeloid, Acute 2 Glioma 2 Breast Neoplasms 2 Brain Neoplasms 2 Advanced Solid Tumors 2 Adenocarcinoma of Lung 2 Thyroid Carcinoma, Anaplastic 1 Thrombocytosis 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors, KRAS Mutation; SOS1 1 Solid Tumors 1 Solid Tumor Cancer 1 Solid Tumor 1 Sarcoma 1 Rhabdoid Tumor 1 Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer 1 Recurrence 1

Interventions

Nivolumab 8 Paclitaxel 6 Sirolimus 5 Bevacizumab 5 temsirolimus 4 Pemetrexed 4 Ipilimumab 4 Docetaxel 4 Carboplatin 4 ARRY-334543 4 Gemcitabine 3 Erlotinib Hydrochloride 3 olaparib 2 linrodostat 2 apatinib 2 anlotinib 2 abemaciclib 2 Vorinostat 2 Sunitinib 2 Magnetic Resonance Spectroscopy 2 Irinotecan 2 Everolimus 2 Doxorubicin 2 Dasatinib 2 Chlorogenic Acid 2 Cetuximab 2 6-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2 vorolanib 1 vistusertib 1 trametinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Advanced Cancer × trametinib × Clear all

NCT01287546 2017-02-15

A Study of LY2875358 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡